Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy

References

• Bradford PA, Bratu S, Urban C, Visalli M, Mariano N, Landman D, et al. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin Infect Dis 2004;39:55–60.
   PubMed Web of Science ®Google Scholar
• Bratu S, Landman D, Haag R, Recco R, Eramo A, Alam M, Quale J. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005;165:1430–5.
   PubMed Web of Science ®Google Scholar
• Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006–09). J Antimicrob Chemother 2011;66:2070–4.
   PubMed Web of Science ®Google Scholar
• Amin A. Clinical and economic consequences of ventilator-associated pneumonia. Clin Infect Dis 2009;49(Suppl 1): S36–43.
   Google Scholar
• Herwaldt LA, Cullen JJ, Scholz D, French P, Zimmerman MB, Pfaller MA, et al. A prospective study of outcomes, healthcare resource utilization, and costs associated with postoperative nosocomial infections. Infect Control Hosp Epidemiol 2006;27:1291–8.
   PubMed Web of Science ®Google Scholar
• Nadkarni AS, Schliep T, Khan L, Zeana CB. Cluster of bloodstream infections caused by KPC-2 carbapenemase-producing Klebsiella pneumoniae in Manhattan. Am J Infect Control 2009;37:121–6.
   PubMed Web of Science ®Google Scholar
• Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 2013;57:524–31.
   PubMed Web of Science ®Google Scholar
• Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011;55:3284–94.
   PubMed Web of Science ®Google Scholar
• Tripodi MF, Durante-Mangoni E, Fortunato R, Utili R, Zarrilli R. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases. Int J Antimicrob Agents 2007;30:537–40.
   PubMed Web of Science ®Google Scholar
• Souli M, Rekatsina PD, Chryssouli Z, Galani I, Giamarellou H, Kanellakopoulou K. Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-beta-lactamase-producing Klebsiella pneumoniae isolates?. Antimicrob Agents Chemother 2009;53:2133–5.
   PubMed Web of Science ®Google Scholar
• Elemam A, Rahimian J, Doymaz M. In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase- producing Klebsiella pneumoniae. J Clin Microbiol 2010;48: 3558–62.
   PubMed Web of Science ®Google Scholar
• Quale J, Shah N, Kelly P, Babu E, Backer M, Rosas-Garcia G, et al. Activity of polymyxin B and the novel polymyxin analogue CB-182,804 against contemporary Gram-negative pathogens in New York City. Microb Drug Resist 2012; 18:132–6.
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 2013;57:349–58.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012;55:943–50.
   PubMed Web of Science ®Google Scholar
• Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012;56:2108–13.
   PubMed Web of Science ®Google Scholar
• Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al.; SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250–6.
   PubMed Web of Science ®Google Scholar
• Gilbert D, Moellering R, Eliopoulos G. The Sanford guide to antimicrobial therapy; 2012.
   Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 19th Informational supplement. CLSI document M100-S19. Wayne, PA, USA: Clinical and Laboratory Standards Institute; 2009.
   Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373–83.
   PubMedGoogle Scholar
• Zimmerman JE, Kramer AA, McNair DS, Malila FM. Acute Physiology and Chronic Health Evaluation (APACHE) IV: hospital mortality assessment for today's critically ill patients. Crit Care Med 2006;34:1297–310.
   PubMed Web of Science ®Google Scholar
• Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204–12.
   PubMed Web of Science ®Google Scholar
• Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41.
   PubMed Web of Science ®Google Scholar
• Bergen PJ, Landersdorfer CB, Zhang J, Zhao M, Lee HJ, Nation RL, Li J. Pharmacokinetics and pharmacodynamics of ‘old’ polymyxins: what is new?. Diagn Microbiol Infect Dis 2012;74:213–23.
   PubMed Web of Science ®Google Scholar
• Zavascki AP, Carvalhaes CG, Picão RC, Gales AC. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther 2010;8:71–93.
   PubMed Web of Science ®Google Scholar
• Kvitko CH, Rigatto MH, Moro AL, Zavascki AP. Polymyxin B versus other antimicrobials for the treatment of Pseudomonas aeruginosa bacteraemia. J Antimicrob Chemother 2011;66:175–9.
   PubMed Web of Science ®Google Scholar
• Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, et al. Predictors of mortality in patients with bloodstream infections caused by KPC- producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 2011;17: 1798–803.
   PubMed Web of Science ®Google Scholar
• Harris AD, Nemoy L, Johnson JA, Martin-Carnahan A, Smith DL, Standiford H, Perencevich EN. Co-carriage rates of vancomycin-resistant Enterococcus and extended-spectrum beta-lactamase-producing bacteria among a cohort of intensive care unit patients: implications for an active surveillance program. Infect Control Hosp Epidemiol 2004;25:105–8.
   PubMed Web of Science ®Google Scholar
• Viau RA, Hujer AM, Marshall SH, Perez F, Hujer KM, Briceño DF, et al. “Silent” dissemination of Klebsiella pneumoniae isolates bearing K. pneumoniae carbapenemase in a long-term care facility for children and young adults in Northeast Ohio. Clin Infect Dis 2012;54:1314–21.
   PubMed Web of Science ®Google Scholar
• Marchaim D, Perez F, Lee J, Bheemreddy S, Hujer AM, Rudin S, et al. “Swimming in resistance”: co-colonization with carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii or Pseudomonas aeruginosa. Am J Infect Control 2012;40:830–5.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Carbapenem-resistant Klebsiella pneumoniae associated with a long-term care facility—West Virginia, 2009–2011. MMWR Morb Mortal Wkly Rep 2011;60:1418–20.
   PubMedGoogle Scholar
• Siegel JD, Rhinehart E, Jackson M, Chiarello L; Health Care Infection Control Practices Advisory Committee. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings. Am J Infect Control 2007;35(10 Suppl 2):65–164.
   Web of Science ®Google Scholar
• Kubin CJ, Ellman TM, Phadke V, Haynes LJ, Calfee DP, Yin MT. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect 2012;65:80–7.
   PubMed Web of Science ®Google Scholar
• Akajagbor D, Wilson S, Shere-Wolfe KD, Dakum P, Charurat M, Gilliam BL. Higher incidence of acute kidney injury (AKI) with intravenous colistin (colistimethate sodium) compared to PB (polymyxin B) in critically ill patients at a tertiary care medical center. Clin Infect Dis 2013;57:1300–1303.
   PubMed Web of Science ®Google Scholar
• Teng CB, Koh PT, Lye DC, Ang BS. Continuous versus intermittent infusion of polymyxin B in the treatment of infections caused by multidrug-resistant Gram-negative bacteria. Int J Antimicrob Agents 2008;31:80–2.
   PubMed Web of Science ®Google Scholar
• Vicari G, Bauer SR, Neuner EA, Lam SW. Association between colistin dose and microbiologic outcomes in patients with multi-drug resistant Gram-negative bacteremia. Clin Infect Dis 2013;56:398–404.
   PubMed Web of Science ®Google Scholar
• Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 2012;67:1607–15.
   PubMed Web of Science ®Google Scholar
• Dubrovskaya Y, Chen TY, Scipione MR, Esaian D, Phillips MS, Papadopoulos J, Mehta SA. Polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections: risk factors for treatment failure. Antimicrob Agents Chemother 2013;57:5394–5397.
   PubMed Web of Science ®Google Scholar
• Endimiani A, Hujer KM, Hujer AM, Armstrong ES, Choudhary Y, Aggen JB, Bonomo RA. ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. Antimicrob Agents Chemother 2009;53:4504–7.
   PubMed Web of Science ®Google Scholar
• Stachyra T, Levasseur P, Péchereau MC, Girard AM, Claudon M, Miossec C, Black MT. In vitro activity of the beta-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J Antimicrob Chemother 2009;64:326–9.
   PubMed Web of Science ®Google Scholar